Regulation of myeloidderived suppressor cells by prostaglandin E2 in tumor microenvironment

doi:10.3760/cma.j.issn.1673422X.2017.03.006

Abstract

Abstract: Myeloidderived suppressor cells (MDSCs), a heterogeneous population of immature myeloid cells, play an important role in immune tolerance and immune suppression. In recent years, more and more research results show that the prostaglandin E2 (PGE2) has an inseparable relationship with MDSCs, and PGE2 through its relevant receptors, regulating signal transducer and activator of transcription 3 (STAT3) and protein kinase A cell signaling pathways and secretion cytokines in tumor microenvironment, affects the development, differentiation and function of MDSCs.

Key words: Dinoprostone, Bone marrow, Cells, Neoplasms

Xie Huilan, Zhang Minhao, Gu Lianbing, Bao Hongguang. Regulation of myeloidderived suppressor cells by prostaglandin E2 in tumor microenvironment[J]. Journal of International Oncology, 2017, 44(3): 182-185.

References

［1］ Kalinski P. Regulation of immune responses by prostaglandin E2［J］. J Immunol, 2012, 188(1): 21-28. DOI: 10.4049/jimmunol.1101029. ［2］ O′callaghan G, Houston A. Prostaglandin E2 and the EP receptors in malignancy: possible therapeutic targets?［J］. Br J Pharmacol, 2015, 172(22): 5239-5250. DOI: 10.1111/bph.13331. ［3］ Liu B, Qu L, Yan S. Cyclooxygenase2 promotes tumor growth and suppresses tumor immunity［J］. Cancer Cell Int, 2015, 15: 106. DOI: 10.1186/s1293501502607. ［4］ Marvel D, Gabrilovich DI. Myeloidderived suppressor cells in the tumor microenvironment: expect the unexpected［J］. J Clin Invest, 2015, 125(9): 3356-3364. DOI: 10.1172/JCI80005. ［5］ Dolcetti L, Peranzoni E, Ugel S, et al. Hierarchy of immunosuppressive strength among myeloidderived suppressor cell subsets is determined by GMCSF［J］. Eur J Immunol, 2010, 40(1): 22-35. DOI: 10.1002/eji.200939903. ［6］ Youn JI, Nagaraj S, Collazo M, et al. Subsets of myeloidderived suppressor cells in tumorbearing mice［J］. J Immunol, 2008, 181(8): 5791-5802. ［7］ Movahedi K, Guilliams M, Van den Bossche J, et al. Identification of discrete tumorinduced myeloidderived suppressor cell subpopulations with distinct T cellsuppressive activity［J］. Blood, 2008, 111(8): 4233-4244. DOI: 10.1182/blood200707099226. ［8］ Filipazzi P, Huber V, Rivoltini L. Phenotype, function and clinical implications of myeloidderived suppressor cells in cancer patients［J］. Cancer Immunol Immunother, 2012, 61(2): 255-263. DOI: 10.1007/s0026201111619. ［9］ Sinha P, Clements VK, Fulton AM, et al. Prostaglandin E2 promotes tumor progression by inducing myeloidderived suppressor cells［J］. Cancer Res, 2007, 67(9): 4507-4513. DOI: 10.1158/00085472.CAN064174. ［10］ Xiang X, Poliakov VK, Liu C, et al. Induction of myeloidderived suppressor cells by tumor progression by inducing myeloidderived suppressor cells［J］. Int J Cancer, 2009, 124(11): 2621-2633. ［11］ Lee H, Pal SK, Reckamp K, et al. STAT3: a target to enhance antitumor immune response［J］. Curr Top Microbiol Immunol, 2011, 344: 41-59. DOI: 10.1007/82_2010_51. ［12］ Mao Y, Poschke I, Wennerberg E, et al. Melanomaeducated CD14+ cells acquire a myeloidderived suppressor cell phenotype through COX2dependent mechanisms［J］. Cancer Res, 2013, 73(13): 3877-3887. DOI: 10.1158/00085472.CAN124115. ［13］ Liu Q, Zhang M, Jiang X, et al. miR223 suppresses differentiation of tumorinduced CD11b+ Gr1+ myeloidderived suppressor cells from bone marrow cells［J］. Int J Cancer, 2011, 129(11): 2662-2673. DOI: 10.1002/ijc.25921. ［14］ Johnnidis JB, Harris MH, Wheeler RT, et al. Regulation of progenitor cell proliferation and granulocyte function by microRNA223［J］. Nature, 2008, 451(7182): 1125-1129. DOI: 10.1038/nature06607. ［15］ Rong Y, Yuan CH, Qu Z, et al. Doxorubicin resistant cancer cells activate myeloidderived suppressor cells by releasing PGE2［J］. Sci Rep, 2016, 6: 23824. DOI: 10.1038/srep23824. ［16］ Tecchio C, Cassatella MA. Neutrophilderived chemokines on the road to immunity［J］. Semin Immunol, 2016, 28(2): 119-128. DOI: 10.1016/j.smim.2016.04.003. ［17］ Obermajer N, Muthuswamy R, Odunsi K, et al. PGE(2)induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment［J］. Cancer Res, 2011, 71(24): 7463-7470. DOI: 10.1158/00085472.CAN112449. ［18］ Fujita M, Kohanbash G, FellowsMayle W, et al. COX2 blockade suppresses gliomagenesis by inhibiting myeloidderived suppressor cells［J］. Cancer Res, 2011, 71(7): 2664-2674. DOI: 10.1158/00085472.CAN103055. ［19］ Kim R, Emi M, Tanabe K, et al. Tumordriven evolution of immunosuppressive networks during malignant progression［J］. Cancer Res, 2006, 66(11): 5527-5536. DOI: 10.1158/00085472.CAN054128. ［20］ Zhang Y, Liu Q, Zhang M, et al. Fas signal promotes lung cancer growth by recruiting myeloidderived suppressor cells via cancer cellderived PGE2［J］. J Immunol, 2009, 182(6): 3801-3808. DOI: 10.4049/jimmunol.0801548. ［21］ Pyzer AR, Cole L, Rosenblatt J, et al. Myeloidderived suppressor cells as effectors of immune suppression in cancer［J］. Int J Cancer, 2016, 139(9): 1915-1926. DOI: 10.1002/ijc.30232. ［22］ Zhao Y, Wu T, Shao S, et al. Phenotype, development, and biological function of myeloidderived suppressor cells［J］. Oncoimmunology, 2016, 5(2): e1004983. DOI: 10.1080/2162402X.2015.1004983. ［23］ Rodriguez PC, Hernandez CP, Quiceno D, et al. Arginase Ⅰ in myeloid suppressor cells is induced by COX2 in lung carcinoma［J］. J Exp Med, 2005, 202(7): 931-939. DOI: 10.1084/jem.20050715. ［24］ Talmadge JE, Hood KC, Zobel LC, et al. Chemoprevention by cyclooxygenase2 inhibition reduces immature myeloid suppressor cell expansion［J］. Int Immunopharmacol, 2007, 7(2): 140-151. DOI: 10.1016/j.intimp.2006.09.021. ［25］ Lechner MG, Liebertz DJ, Epstein AL. Characterization of cytokineinduced myeloidderived suppressor cells from normal human peripheral blood mononuclear cells［J］. J Immunol, 2010, 185(4): 2273-2284. DOI: 10.4049/jimmunol.1000901. ［26］ Huang B, Pan PY, Li Q, et al. Gr1+CD115+ immature myeloid suppressor cells mediate the development of tumorinduced T regulatory cells and Tcell anergy in tumorbearing host［J］.Cancer Res, 2006, 66(2): 1123-1131. ［27］ Mao Y, Sarhan D, Steven A, et al. Inhibition of tumorderived prostaglandine2 blocks the induction of myeloidderived suppressor cells and recovers natural killer cell activity［J］. Clin Cancer Res, 2014, 20(15): 4096-4106. DOI: 10.1158/10780432.CCR140635. ［28］ Veltman JD, Lambers ME, van Nimwegen M, et al. COX2 inhibition improves immunotherapy and is associated with decreased numbers of myeloidderived suppressor cells in mesothelioma. Celecoxib influences MDSC function［J］. BMC Cancer, 2010, 10: 464. DOI: 10.1186/1471240710464. ［29］ Obermajer N, Muthuswamy R, Lesnock J, et al. Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloidderived suppressor cells［J］. Blood, 2011, 118(20): 5498-5505. DOI: 10.1182/blood201107365825. ［30］ Obermajer N, Kalinski P. Generation of myeloidderived suppressor cells using prostaglandin E2［J］. Transplant Res, 2012, 1(1): 15. DOI: 10.1186/20471440115.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297.